AXA Private Equity has acquired all shares from Mecklenburg-based pharmaceutical manufacturer Riemser Arzneimittel AG.
Riemser, situated in Greifswald, focuses on the distribution and lifecycle management of pharamaceutical products for niche markets, including oncology, infectious diseases and dermatology.
In addition, following its de-merger from Friedrich-Loeffler-Institut, it is the market leader in Tuberculosis Infection and was a company in high demand. As of 2011, Riemser emplyed around 500 employees with a EUR 100 million turnover. Their portfolio includes medical comapny Rösch and Leipziger Arzneimittelwerk production facility.
[ilink url=“http://www.axaprivateequity.com/de/press/Press%20Releases/Press%20Release%20Riemser%20German.pdf“] Link zur Quelle (AXA Private Equity)[/ilink]